دورية أكاديمية
أعرض في EDS

Supramolecular assemblies from antimony(V) complexes for the treatment of leishmaniasis.

التفاصيل البيبلوغرافية
العنوان: Supramolecular assemblies from antimony(V) complexes for the treatment of leishmaniasis.
المؤلفون: Demicheli C; Department of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil., Vallejos VMR; Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil., Lanza JS; Vaxinano, 59120 Loos, France., Ramos GS; Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil., Do Prado BR; Department of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil., Pomel S; Faculty of Pharmacy, Antiparasite Chemotherapy (PARACHEM), UMR 8076 CNRS BioCIS, University Paris-Saclay, 91400 Orsay, France., Loiseau PM; Faculty of Pharmacy, Antiparasite Chemotherapy (PARACHEM), UMR 8076 CNRS BioCIS, University Paris-Saclay, 91400 Orsay, France., Frézard F; Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil.
المصدر: Biophysical reviews [Biophys Rev] 2023 Jun 06; Vol. 15 (4), pp. 751-765. Date of Electronic Publication: 2023 Jun 06 (Print Publication: 2023).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: Germany NLM ID: 101498573 Publication Model: eCollection Cited Medium: Print ISSN: 1867-2450 (Print) Linking ISSN: 18672450 NLM ISO Abbreviation: Biophys Rev Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Heidelberg : Springer
مستخلص: The pentavalent meglumine antimoniate (MA) is still a first-line drug in the treatment of leishmaniasis in several countries. As an attempt to elucidate its mechanism of action and develop new antimonial drugs with improved therapeutic profile, Sb(V) complexes with different ligands, including β-cyclodextrin (β-CD), nucleosides and non-ionic surfactants, have been studied. Interestingly, Sb(V) oxide, MA, its complex with β-CD, Sb(V)-guanosine complex and amphiphilic Sb(V) complexes with N-alkyl-N-methylglucamide, have shown marked tendency to self-assemble in aqueous solutions, forming nanoaggregates, hydrogel or micelle-like nanoparticles. Surprisingly, the resulting assemblies presented in most cases slow dissociation kinetics upon dilution and a strong influence of pH, which impacted on their pharmacokinetic and therapeutic properties against leishmaniasis. To explain this unique property, we raised the hypothesis that multiple pnictogen bonds could contribute to the formation of these assemblies and their kinetic of dissociation. The present article reviews our current knowledge on the structural organization and physicochemical characteristics of Sb-based supramolecular assemblies, as well as their pharmacological properties and potential for treatment of leishmaniasis. This review supports the feasibility of the rational design of new Sb(V) complexes with supramolecular assemblies for the safe and effective treatment of leishmaniasis.
Competing Interests: Conflict of interestThe authors declare no competing interests.
(© International Union for Pure and Applied Biophysics (IUPAB) and Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
References: J Pharm Sci. 1997 Feb;86(2):147-62. (PMID: 9040088)
J Biomol Struct Dyn. 1990 Dec;8(3):491-511. (PMID: 2100515)
Chem Soc Rev. 2017 Oct 30;46(21):6600-6620. (PMID: 28828455)
Parasitol Res. 2019 Oct;118(10):3077-3084. (PMID: 31401656)
J Mater Chem B. 2015 Dec 28;3(48):9250-9259. (PMID: 32262924)
Chem Biol Interact. 2006 Apr 15;160(3):217-24. (PMID: 16524568)
Adv Drug Deliv Rev. 1998 Jun 8;32(1-2):45-60. (PMID: 10837635)
Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10383-7. (PMID: 8816809)
Chem Sci. 2020 Apr 9;11(17):4374-4380. (PMID: 33224458)
Chem Soc Rev. 2017 Oct 30;46(21):6638-6663. (PMID: 29019492)
J Pharm Pharmacol. 1988 May;40(5):370-3. (PMID: 2899637)
Int J Pharm. 2008 Jan 22;347(1-2):102-8. (PMID: 17656054)
J Dermatol. 2018 Sep;45(9):1044-1052. (PMID: 29863755)
Biochim Biophys Acta. 2002 Apr 15;1570(3):192-8. (PMID: 12020809)
Biometals. 2003 Sep;16(3):441-6. (PMID: 12680707)
Antimicrob Agents Chemother. 2014;58(1):481-8. (PMID: 24189251)
Biochem J. 1943 Jul;37(2):198-209. (PMID: 16747617)
Chem Commun (Camb). 2018 Aug 7;54(64):8849-8852. (PMID: 30039149)
Inorg Chem. 2020 Jul 6;59(13):9315-9324. (PMID: 32496762)
Nucl Med Commun. 1985 Aug;6(8):437-41. (PMID: 3877889)
Biopharm Drug Dispos. 2010 Mar;31(2-3):109-19. (PMID: 20014042)
Biophys Rev. 2014 Mar;6(1):119-132. (PMID: 28509965)
Front Immunol. 2022 Apr 14;13:789366. (PMID: 35493523)
J Biol Chem. 2004 Jul 23;279(30):31010-7. (PMID: 15138256)
J Inorg Biochem. 2008 Apr;102(4):656-65. (PMID: 18061680)
Inorg Chem. 2019 Dec 2;58(23):16227-16235. (PMID: 31718176)
Acta Crystallogr C. 1995 May 15;51 ( Pt 5):822-4. (PMID: 7779322)
J Immunol. 2001 Sep 15;167(6):3391-7. (PMID: 11544330)
Acc Chem Res. 2009 Oct 20;42(10):1554-63. (PMID: 19555073)
PLoS Negl Trop Dis. 2017 Dec 14;11(12):e0006052. (PMID: 29240765)
Antimicrob Agents Chemother. 2018 Jul 27;62(8):. (PMID: 29866873)
Int J Nanomedicine. 2016 Dec 13;11:6771-6780. (PMID: 28008252)
J Biol Chem. 2001 Jul 13;276(28):26301-7. (PMID: 11306588)
J Inorg Biochem. 2005 Dec;99(12):2257-63. (PMID: 16214217)
Pharmaceutics. 2022 Aug 21;14(8):. (PMID: 36015369)
Molecules. 2009 Jun 30;14(7):2317-36. (PMID: 19633606)
Antimicrob Agents Chemother. 2008 Mar;52(3):1080-93. (PMID: 18056276)
Int J Nanomedicine. 2016 May 25;11:2305-18. (PMID: 27307731)
Inorg Chem. 2017 Jul 17;56(14):8372-8380. (PMID: 28650624)
Trop Med Int Health. 2019 Apr;24(4):380-391. (PMID: 30681239)
Phys Chem Chem Phys. 2021 Jun 30;23(25):13842-13852. (PMID: 34155488)
Antimicrob Agents Chemother. 2013 Sep;57(9):4229-4236. (PMID: 23796930)
Adv Drug Deliv Rev. 1999 Mar 1;36(1):125-141. (PMID: 10837712)
Mater Today Bio. 2022 Jun 15;15:100327. (PMID: 35757027)
J Biol Chem. 2004 Sep 17;279(38):39925-32. (PMID: 15252045)
Int J Pharm. 2006 Nov 15;325(1-2):39-47. (PMID: 16876345)
J Biol Inorg Chem. 2003 Jul;8(6):689-97. (PMID: 12827457)
Biometals. 2006 Oct;19(5):573-81. (PMID: 16937264)
Antimicrob Agents Chemother. 1998 May;42(5):1076-82. (PMID: 9593130)
Expert Opin Pharmacother. 2015 Feb;16(2):237-52. (PMID: 25346016)
J Med Chem. 2009 Apr 23;52(8):2603-12. (PMID: 19317451)
J Pharm Sci. 1996 Nov;85(11):1142-69. (PMID: 8923319)
J Biol Chem. 2004 Sep 3;279(36):37445-51. (PMID: 15220340)
Clin Infect Dis. 1997 Apr;24(4):684-703. (PMID: 9145744)
J Antimicrob Chemother. 2004 Jul;54(1):60-8. (PMID: 15163652)
Antimicrob Agents Chemother. 2004 Jan;48(1):100-3. (PMID: 14693525)
فهرسة مساهمة: Keywords: Antimony; Drug delivery; Leishmaniasis; Nanoassemblies; Pnictogen bonding; Supramolecular
تواريخ الأحداث: Date Created: 20230908 Latest Revision: 20240607
رمز التحديث: 20240607
مُعرف محوري في PubMed: PMC10480371
DOI: 10.1007/s12551-023-01073-6
PMID: 37681109
قاعدة البيانات: MEDLINE
الوصف
تدمد:1867-2450
DOI:10.1007/s12551-023-01073-6